UNSPSC 51291701: Venlafaxine

This classification denotes an antidepressant agent with the molecular formula C17H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GRZ5RCB1QG, chemically known as cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)- but generally known as venlafaxine, which bears US NIH Compound Identifier 5656. European Medicines Agency schedules Venlafaxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00034MIG.

UNSPSC 51291701 Venlafaxine, a Commodity code, nominally identifies a single pharmaceutical product, but recent state and local procurement activity under this code spans a broader range of pharmaceutical and drug-related products and services. The code shows minimal direct solicitation for venlafaxine itself; instead, issuing bodies are using it to tag opportunities for naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals distributed through cooperative purchasing vehicles. State and local buyers under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being solicited ranges from routine procurement of finished naloxone and drug deactivation systems for community health programs to exploratory market-intelligence gathering on direct pharmacy contracting models and large-scale generic pharmaceutical supply agreements across multiple jurisdictions.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; vendors must provide all shipping and delivery costs and meet standard compliance requirements including E-Verify and workers' compensation insurance. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a preliminary information-gathering phase with no budget or award values specified. MMCAP, administered by Minnesota's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 with a response deadline of March 26, 2026, for multiple contracts covering generic multi-source pharmaceuticals and OTC products for participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and compliance criteria; contract pricing was effective July 1, 2026.